Agenus Commences Phase 2 Study of HerpV Vaccine for the Treatment of Genital Herpes

Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission for the period ended June 30, 2011. HerpV is a recombinant therapeutic vaccine for the treatment of genital herpes, which is caused by the herpes simplex virus-2 (HSV-2). HSV-2 is a lifelong and incurable infection that can cause recurrent and painful genital sores. The vaccine was generally well tolerated, with injection site pain as the most common reported adverse event. HCT recipients are at increased risk for viremia and visceral dissemination during shingles, which occurs in approximately 10% to 30% of patients with severely impaired cellular immunity7, 8.

The emotional consequences of genital herpes are quite significant, as 82 percent of people in the study reported depression, 75 percent experienced fear of rejection, 69 percent cited feelings of isolation and 55 percent reported fear of discovery — all due to infection(3). We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. These types of herbs are more effective when used properly and cautiously. Their next-generation vaccines are much more likely than Glaxo’s to succeed. It’s in a better position, in fact, than Agenus’ HerpV, according to a GlobalData analyst. Dear Staying Upbeat, thank you for your query.


Agenus (AGEN) Announces Publication of Positive Data from GSK’s Shingles Vaccine + QS-21 in NEJM. Glencore forfeited 0. Garvie are working on a vaccine against herpes. The vaccine was generally well tolerated, with injection site pain as the most common reported adverse event. Its Oncept vaccine for Canine Melanoma, a collaboration with Merial, has been approved by the U. That was in December of 2014, and we are waiting to hear about whether GSK will use this data for a regulatory submission.

, Professor of Allergy and Infectious Diseases, University of Washington. . I was diagnosed herpes 2 five years ago. An ideal herpes vaccine should induce immune responses adequate to prevent infection. (Nasdaq: AGEN) , a developer of therapeutic vaccines for cancer and infectious diseases, today announced it has completed patient screening in its Phase 2 randomized, double-blind, multicenter study for HerpV, a recombinant off-the-shelf therapeutic vaccine candidate for the treatment of genital herpes in herpes simplex virus-2 (HSV-2) positive patients. So we haven’t looked at it, Bryan, in the Phase 1.

Let me just say that there is a reasonable chance for success. During this call, we will review our financial results as well as provide a corporate update. HSV or Herpes simplex virus leads to genital and oral fever blisters whereas Herpes zoster is accountable for shingles. The HerpV Phase 2 study design was defined by key opinion leaders in the field. The Prophage Series G vaccines (HSPPC-96; vitespen) are being studied in two different settings of glioma: newly diagnosed and recurrent disease. GNCA UPDATED: Analyst: Genocea’s genital herpes vaccine better positioned than Agenus’ to enter market fiercevaccines.com/story/an.

So get a handful of throat lozenges from the local pharmacy store and suck on them as long as the cough is not cured. For the fourth quarter, Agenus reported a net loss attributable to common stockholders of $5.8 million, or $0.16 per share, basic and diluted, compared with a net loss attributable to common stockholders for the fourth quarter of 2012 of $5.6 million, or $0.23 per share, basic and diluted. Specificity will be reported as the percentage of subjects without an HSV infection who test negative by the Aptima HSV 1 & 2 assay. If you disclose, you go straight to the bottom of the barrel and your sexual value hits near zero. As immunotherapy becomes a fast-moving field, Agenus embraces its business model around its three central, imperative and promising platforms – Checkpoint Antibody Program, Heat Shock Protein and Saponin Platforms – to construct innovative development of checkpoint modulators (CPMs), heat shock protein vaccines and adjuvants that can be used in wide spectrum of vaccines and, ultimately, revolutionize vaccines of tomorrow. In the summer, usually shower after working up a large perspiration.